Difference in Presence and Number of CD83+ Dendritic Cells in Patients with Ulcerative Colitis and Crohn’s Disease

There were 154 subjects included in this study: 60 with ulcerative colitis, 19 with Crohn’s disease and 75 in the control group. Colonic biopsy was performed in all subjects. Specimens were incubated with a primary anti-CD83 antibody.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Macrophage Metabolic Reprogramming Presents a Therapeutic Target in Lupus Nephritis

Investigators found that human and mouse macrophages underwent a switch to glycolysis in response to IgG immune complex stimulation, mirroring macrophage metabolic changes in inflamed tissue in vivo. This metabolic reprogramming was required to generate a number of proinflammatory mediators, including IL-1β, and was dependent on mTOR and hypoxia-inducible factor-1α.
[Proceedings of the National Academy of Sciences of the United States of America]
Full Article
Bookmark

No account yet? Register

0
Share

Determinants of Resident Tissue Macrophage Identity and Function

The authors review recent findings within this context and discuss the technological advances that are revolutionizing the study of macrophage biology.
[Immunity]
Abstract
Bookmark

No account yet? Register

0
Share

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

The authors explore current strategies that shift immune cell metabolism to pro-inflammatory states in the tumor microenvironment and highlight a need to better replicate physiologic conditions to select targets, clarify mechanisms, and optimize metabolic inhibitors.
[Molecular Cell]
Abstract
Bookmark

No account yet? Register

0
Share

Tumor-Induced Neurogenesis and Immune Evasion as Targets of Innovative Anti-Cancer Therapies

The authors discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, they also focus on anti-immunosuppression-based therapies.
[Signal Transduction and Targeted Therapy]
Full Article
Bookmark

No account yet? Register

0
Share

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs). JAK inhibition, therefore, presents an attractive therapeutic strategy for cytokine release syndrome, which is a common cause of adverse clinical outcomes in COVID-19.
[Trends in Pharmacological Sciences]
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020). Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19. Trends in Pharmacological Sciences, 0(0). https://doi.org/10.1016/j.tips.2020.06.007 Cite
Full Article
Bookmark

No account yet? Register

0
Share

UCLA Receives Nearly $14 Million from NIH to Investigate Gene Therapy to Combat HIV

University of California, Lost Angeles (UCLA) researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
[Univesity of California, Los Angeles]
Graphical Abstract
Bookmark

No account yet? Register

0
Share

Exosomes: A Potential Therapeutic Tool Targeting Communications between Tumor Cells and Macrophages

Scientists summarize the roles and mechanisms of exosomes in the interaction between tumor cells and macrophages and the potential methods by which exosomes are used to target the communication between tumor cells and macrophages to treat cancer.
[Molecular Therapy]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo

The authors created a chimeric antigen-receptor (CAR) that was capable of on-demand downregulation by fusing the CAR to a previously developed ligand-induced degradation domain. Addition of a small molecule ligand triggered exposure of a cryptic degron within the ligand-induced degradation domain (LID), resulting in proteasomal degradation of the CAR-LID fusion protein and loss of CAR on the surface of T cells.
[Molecular Therapy]
Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo: Molecular Therapy. (n.d.). Retrieved June 16, 2020, from https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30294-X Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

CRISPR-Cas9 Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T-Cell Therapy Post Transplantation

In order to deliver protection against viral pathogens and allow at the same time necessary steroid therapy, scientists generated glucocorticoid-resistant T cells by CRISPR/Cas9-mediated knockout of the glucocorticoid receptor in primary human virus-specific T-cell products.
[Molecular Therapy]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Novel Long Non-Coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression

The biological capacity of lncRNA named lncRNA activated in metastatic PCa (lncAMPC) in prostate cancer (PCa) was demonstrated both in vitro and in vivo. The lncAMPC was overexpressed in tumor tissue and urine of metastatic PCa patients and promoted PCa tumorigenesis and metastasis.
[Molecular Therapy]
Zhang, W., Shi, X., Chen, R., Zhu, Y., Peng, S., Chang, Y., … Ren, S. (2020). Novel long non-coding RNA lncAMPC promotes metastasis and immunosuppression in prostate cancer by stimulating LIF/LIFR expression. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2020.06.013 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share
Share